During the first year of the Trump administration, signs of an anti-mRNA slant within the FDA and HHS became more and more ...
AstraZeneca is taking its oral GLP-1 drug into phase 3 on the back of a pair of midstage weight loss wins, despite remaining ...
Nektar Therapeutics is basking in the honeyed glow of long-term phase 2 data for its immune asset rezpegaldesleukin in atopic ...
In October of last year, Kailera Therapeutics unveiled a whopping $600 mill | Kailera Therapeutics and its China partner ...
ILiAD Biotechnologies has closed an oversubscribed $115 million series B fundraise to support the company’s next-generation ...
German Merck has set up a new collaboration with U.K. medtech company Calla Lily Clinical Care to work on its next-generation ...
There is a history of studying relaxin in cardiovascular settings—Novartis started a phase 3 heart failure trial of a recombinant relaxin-2 peptide in 2013—but preclinical evidence of the molecule’s ...
Evommune has aced its first major test as a public company, reporting phase 2a eczema data that caused its share price to jump 75% in premarket trading. The biotech, which went public late last year, ...
OrsoBio’s experimental oral drug lowered fasting triglyceride levels at four weeks of treatment, hitting the primary efficacy goal in a midstage study of metabolic conditions. | OrsoBio’s experimental ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results